CELLINK

Company Snapshot

Founded: 2016
Entity Type: Private
Region: Sweden
Headquarter: Gothenburg, Sweden
Key Geographics: North America, Latin America, Europe, Asia, Middle East and Africa
Corporate Address: Langfilsgatan 1, 412 77 Gothenburg, Sweden Tel.: +46-31-12-8700 Web.: www.cellink.com

Company Overview

Cellink is a biotech company based in Sweden and the U.S. it commercializes bioinks for 3D bioprinting of human organs and tissue. Its products are consumed in various applications, including tissue engineering, cancer research, disease models, and drug testing. It operates as a subsidiary of BICO.

Erik Gatenholm, co-founder and CEO of Cellink, started his first biomedical device company in Blacksburg, Va., in 2008, commercializing a licensed university technology (from Virginia Polytechnic Institute and State University) into BC Genesis focused on developing cellulose-based medical implants for applications such as meniscus/cartilage repair as well as surgical meshes.

CELLINK In Reports

Laboratory Animal Models, 3D Cultures, and Organoids: Global Markets

BCC Research Market Analyst says global market for laboratory animal models, 3D cultures, and organoids is estimated to increase from $2.8 billion in 2024 to reach $5.0 billion by 2029.

3D Printing Medical Devices: Global Markets

BCC Research Market Analyst says global market for 3D printing medical devices reached $2.1 billion in 2023 & estimated to grow from $2.2 billion in 2024 to $4.5 billion by the end of 2029.

Bioprinting: Technologies and Global Markets

Global bioprinting technologies market should reach $5.0 billion by 2027 from $2.4 billion in 2022 at a CAGR of 16.2% for the forecast period of 2022-27.

Company's Business Segments

  • 3D Bioprinting : This segment includes Bioprinters, Biodispensing, Bioinks, 3D cell culturing.

Applications/End User Industries

  • Academic Researchers
  • Drug Discovery
  • Personalized Medicine
  • Regenerative Medicine
  • Cell-cultured Meat
  • Healthcare
  • Biotechnology
  • Pharmaceuticals
  • Life Sciences
AI Sentiment